Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report

Cay H. F., Gungor H. A., Sezer I., Kacar C., Balci N.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.31, sa.6, ss.645-648, 2006 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 6
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1111/j.1365-2710.2006.00779.x
  • Dergi Adı: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.645-648
  • Anahtar Kelimeler: ankylosing spondylitis, anti-tumour necrosis factor-alpha drugs, transverse myelitis, MULTIPLE-SCLEROSIS PATIENTS, ACUTE TRANSVERSE MYELITIS, NECROSIS, THERAPY, ASSOCIATION, FEATURES
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Anti-tumour necrosis factor (TNF)-alpha agents promise better disease control for treatment of inflammatory arthritides which are resistant to classical disease-modifying treatment and provide better functional outcome. But these agents are not free of adverse events. The exact relationship between use of anti-TNF drugs and development of demyelination cannot be established yet. Here we present a case of a 36-year-old man who developed demyelination in the cervical spinal cord while he was being treated with etanercept for ankylosing spondylitis.